COPD in China Forecast

Published by: Datamonitor

Published: Dec. 14, 2011 - 6 Pages


Table of Contents

OVERVIEW
Summary
OVERVIEW
This product contains COPD market and product forecasts for China over 2011 to 2020. It has been designed for delivery in an Excel data pack format. For more detail about this disease area please see the accompanying Market and Product Forecasts: COPD in China (HC000141-004) PDF document and PowerPoint executive presentation.
The associated report and PowerPoint presentation can be found under Latest Research in the Knowledge Center, through the search function, or by contacting your sales representative.
Please select the data pack option from the download menu at the side of the page to access the model.
Introduction
Features and benefits
Highlights
Key questions answered in this report
Forecasting methodology
Disclaimer

Abstract

Introduction

The increasing prevalence of COPD and new therapies will boost the Chinese COPD market from $204m to $317m by 2020. Spiriva will become the market leader from 2013 and maintain the position through 2020, owing to its wide application across all disease severities. A number of novel products will increase the product offering on the market, with most pipeline products aimed at more severe patients.

Features and benefits
  • Access Datamonitor’s patient based COPD market forecast in China, with transparent methodology and clear assumptions.
  • Explore the current and future market size of COPD in China and see which key brands will impact the market.
  • Gain insight into COPD market dynamics, and see where untapped market potential remains.
  • Understand which factors are driving growth in the Chinese COPD market, and what challenges pipeline products face.
Highlights

Datamonitor forecasts the Chinese COPD market to increase from $204m in 2011 to $317m by 2020, with a compound annual growth rate (CAGR) over 2011–20 of 5.0%. Market growth will not only be boosted by patients continuing to switch to more convenient, and more expensive, combination drugs, but also by the increasing prevalence of COPD in China.Datamonitor forecasts that five new therapies will enter the Chinese market over 2011–20, including the first once-daily ICS/LABA combination and LABA/LAMA combinations. While these combinations are clinically attractive, their commercial potential will be held back by their relatively high price.Datamonitor estimates that in 2011 Seretide and Spiriva top all brands by achieving $48m and $46m respectively, together capturing 46% of the Chinese COPD market. Spiriva will face competition from several pipeline products after 2013, but its wide clinical application across all disease severities will allow it to maintain its market dominance.

Your key questions answered
  • How large is the current COPD market size in China and how is it expected to change over the next 10 years?
  • What restrictions will novel therapies face upon launching in the Chinese COPD market?
  • How will current market leaders be impacted by additional product launches?
  • What role do Chinese regulations play in COPD market dynamics, and how does this impact product use?


Get full details about this report >>
 
Learn more about this product


Price and delivery options
Search Inside Report

US: 800.298.5699

Int'l: +1.240.747.3093

 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports, company profiles and country profiles from over 720 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.